Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246596 | 0.93 | CCR2 (0.36) | CCR2 | |
| SCHEMBL6105380 | 0.91 | — | — | |
| SCHEMBL37603 | 0.91 | — | — | |
| SCHEMBL22510032 | 0.87 | CCR2 (0.39) | CCR2 | |
| SCHEMBL27467506 | 0.84 | NISCH (0.34) | — | |
| SCHEMBL27451622 | 0.82 | NISCH (0.38) | — | |
| SCHEMBL918438 | 0.82 | NISCH (0.38) | — | |
| SCHEMBL9416877 | 0.80 | — | — | |
| SCHEMBL28230760 | 0.79 | HTR3A (0.35) | — | |
| SCHEMBL9095092 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024048405-A1 | CARBON DIOXIDE ABSORPTION AND REDUCTION SOLUTION, CARBON DIOXIDE ABSORPTION AND REDUCTION DEVICE, AND CARBON DIOXIDE ABSORPTION AND REDUCTION METHOD | 三菱重工業株式会社 | 2024-03-07 | — | — | WO | claimed |
| WO-2018217811-A1 | SYNTHESIS OF ETP DERIVATIVES | CITY OF HOPE (US) | 2018-11-29 | — | — | WO | claimed |
| US-9379402-B2 | Anion conducting electrolyte membrane and manufacturing method thereof | JAPAN ATOMIC ENERGY AGENCY (JP) | 2016-06-28 | — | — | US | claimed |
| EP-2882877-A2 | USE OF METAL SCAVENGERS FOR REMOVAL OF RUTHENIUM RESIDUES | Apeiron Synthesis S.A. (PL) | 2015-06-17 | — | — | EP | claimed |
| WO-2014174501-A2 | USE OF METAL SCAVENGERS FOR REMOVAL OF RUTHENIUM RESIDUES | APEIRON SYNTHESIS S.A. (PL) | 2014-10-30 | — | — | WO | claimed |
| US-20130280626-A1 | ANION CONDUCTING ELECTROLYTE MEMBRANE AND MANUFACTURING METHOD THEREOF | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2013-10-24 | — | — | US | claimed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | claimed |
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | claimed |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | claimed |
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | claimed |
| US-5731299-A | OSTEOPOROSIS; RHEUMATOID ARTHRITIS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-24 | — | — | US | claimed |
| EP-0788362-A1 | PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1997-08-13 | — | — | EP | claimed |
| EP-0646119-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-04-05 | — | — | EP | claimed |
| EP-0642518-A1 | PHOSPHONOSULFONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024495-A1 | PHOSPHONOSULFONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | claimed |
| WO-1993024131-A1 | PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | claimed |
| WO-1993024498-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AS WELL AS DENTAL CALCULUS AND PLAQUE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0502733-A1 | Air-activatable polymerisable compositions | LOCTITE (IRELAND) Ltd. (IE) | 1992-09-09 | — | — | EP | claimed |
| EP-0127708-B1 | TRANS-DL-1-ALKYL-6-ALKOXYOCTAHYDROQUINOLINES | ELI LILLY AND COMPANY (US) | 1987-09-09 | — | — | EP | claimed |
| EP-0127708-A1 | Trans-dl-1-alkyl-6-alkoxyoctahydroquinolines | ELI LILLY AND COMPANY (US) | 1984-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | HSD11B1, HSD17B1, HSD11B2 | CCR2 2164/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | CCR2 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.